Ozempic is designed to be taken long-term, and most people who use it will need to continue indefinitely to maintain its benefits. Clinical trials lasting up to four years show that weight loss and blood sugar improvements persist as long as treatment continues, but stopping the medication leads to significant regain. That makes the decision to start Ozempic worth understanding fully, from what years of use look like to what happens to your body along the way.
Why Ozempic Is Considered a Long-Term Medication
Ozempic works by mimicking a gut hormone called GLP-1, which signals fullness to your brain and helps regulate blood sugar. It also appears to shift how your body stores and burns fat, encouraging the conversion of energy-storing white fat into calorie-burning brown fat. These effects only last while the drug is active in your system. Once you stop taking it, the hormonal signals return to their previous patterns, appetite increases, and the metabolic changes reverse.
The STEP 1 trial extension tracked what happened after people stopped semaglutide (the active ingredient in Ozempic). Within one year of stopping, participants regained roughly two-thirds of the weight they had lost. On average, they put back 11.6 percentage points of their prior weight loss. The cardiovascular and metabolic improvements that came with the weight loss also faded. This is why prescribers treat Ozempic the same way they treat blood pressure or cholesterol medications: as ongoing therapy rather than a short course.
What Four Years of Data Show
The longest and largest dataset comes from the SELECT trial, which followed participants for up to four years. Weight loss with semaglutide continued through the first 65 weeks, then held steady for the remaining years. At the four-year mark, people on semaglutide had lost an average of 10.2% of their body weight compared to 1.5% in the placebo group. Waist circumference dropped by 7.7 cm, a meaningful reduction in the visceral fat most closely linked to heart disease and metabolic problems.
The cardiovascular findings from SELECT were significant. About 33% of the heart-related benefit was directly tied to reductions in waist circumference, and lower baseline weight was associated with even greater protection. For every 5 kg of lower body weight, the risk of a major cardiovascular event dropped by roughly 4%. These benefits accumulated over time, reinforcing the case for staying on treatment.
What Happens to Muscle During Extended Use
One of the most common concerns about long-term use is muscle loss. Any time you lose a significant amount of weight, some of that loss comes from lean tissue, not just fat. The SEMALEAN study tracked body composition over 12 months and found a more nuanced picture than the headlines suggest. Total fat mass dropped by 18% over the year. Lean mass did decline initially, dropping about 3 kg in the first seven months, but then stabilized. By 12 months, the proportion of lean mass relative to total body weight had actually increased.
Grip strength, a reliable marker of functional muscle capacity, improved by 4.5 kg at the one-year mark. The prevalence of sarcopenic obesity, a condition where someone carries excess fat alongside dangerously low muscle mass, dropped from 49% to 33%. So while the scale showed some lean tissue loss early on, people’s muscles were functioning better, not worse. Resistance exercise and adequate protein intake likely play a role in preserving muscle during treatment, though the study population wasn’t specifically exercising as part of the protocol.
Nutritional Gaps to Watch For
Because Ozempic suppresses appetite and slows digestion, people on the medication tend to eat significantly less. Over months and years, that reduced intake can create nutritional shortfalls. A cross-sectional study of people taking GLP-1 medications found that the vast majority fell short on several critical nutrients. Nearly 99% of participants consumed less than the recommended amount of vitamin D and potassium. About 94% were low on choline, 90% on magnesium, and 88% on iron. Fiber, calcium, vitamin A, and vitamin C intakes were also below recommended levels.
Protein intake was another concern. Participants were not meeting the grams-per-kilogram-per-day threshold needed to support lean mass during weight loss, which connects directly to the muscle preservation issue. Meanwhile, sodium intake ran 1.4 times above the recommended limit, with nearly 74% of participants exceeding it. This pattern, eating less overall but still gravitating toward salty, processed foods, suggests that long-term users benefit from intentional meal planning or working with a dietitian to make their smaller portions count.
Long-Term Safety Signals
The two-year STEP 5 trial provides the clearest safety snapshot for extended use. Gallbladder-related problems occurred in 2.6% of people on semaglutide versus 1.3% on placebo, a small but real increase consistent with what’s seen during any rapid weight loss. No cases of pancreatitis were reported in either group during the trial. People with a personal or family history of medullary thyroid carcinoma or a related condition called multiple endocrine neoplasia type 2 were excluded from the study, because animal studies showed a thyroid tumor risk that hasn’t been confirmed in humans but warrants caution.
Gastrointestinal side effects, primarily nausea, vomiting, diarrhea, and constipation, are the most common issues. They tend to peak during the dose escalation phase and improve over time. The standard protocol starts at a low dose and increases every four weeks to allow the body to adjust. If side effects persist at the maintenance dose, a temporary step back in dosing for four weeks is a standard approach before trying again. If the full dose remains intolerable, the medication is typically discontinued rather than maintained at a lower, less effective dose.
The Weight Loss Plateau Is Normal
Most people notice their weight loss slowing or stopping around the one-year mark. This isn’t a sign the drug has stopped working. Semaglutide reduces appetite partly by suppressing a nutrient-sensing system in the brain that responds to blood sugar, energy levels, and hunger hormones. As your body reaches a lower weight, the metabolic math changes. You burn fewer calories at rest, your hunger hormones recalibrate, and the gap between energy intake and expenditure narrows. The drug continues to hold weight steady at this new lower point, which is the maintenance phase, not a failure.
The four-year SELECT data confirms this pattern: active weight loss through roughly 65 weeks, then a stable plateau maintained for years. For people with type 2 diabetes, blood sugar control follows a similar trajectory, with improvements in the first year that hold steady with continued use.
What Staying On Ozempic Looks Like
Long-term use means a once-weekly injection, typically self-administered in the thigh, abdomen, or upper arm. There’s no need to time it around meals. Most people settle into a routine quickly, and the injection itself uses a thin, short needle that causes minimal discomfort. Periodic bloodwork to monitor kidney function, blood sugar (for people with diabetes), and nutritional markers is typical during ongoing treatment.
The practical reality for many people is that Ozempic becomes part of their health maintenance, similar to a statin or blood pressure medication. The weight it helps you lose stays off as long as you continue treatment, the cardiovascular protection accumulates over years, and the side effects generally become manageable. The tradeoff is that stopping means losing most of those benefits within a year, which makes the commitment worth understanding before you start.